A four-year clinical trial shows that sublingual immunotherapy (SLIT) for peanut allergies can protect children from accidental exposures for weeks, even after stopping treatment. The treatment uses an amount of peanut protein equivalent to just 1/75th of a peanut kernel, placed under the tongue where it's absorbed by the body. Researchers found that 70% of children achieved protection against accidental peanut exposures, with 36% reaching full desensitization to much larger amounts. What Makes This Peanut Allergy Treatment Different? Unlike Palforzia, the current oral immunotherapy option that requires patients to eat medical-grade peanut flour daily, SLIT offers a simpler approach. The treatment involves a 4 milligram dose of peanut protein taken sublingually—meaning it dissolves under the tongue rather than being swallowed. This method appeals to families who find daily oral treatments stressful or difficult to manage consistently. "Sublingual immunotherapy is not a cure, but by striking that balance of protecting against allergic reactions while still being easy and safe to do, it could have the potential to help a lot of peanut-allergic patients and their families," said Dr. Edwin Kim, associate professor of pediatrics at the University of North Carolina School of Medicine and director of the UNC Food Allergy Initiative. How Long Does the Protection Actually Last? One of the most surprising findings from the research involves what happens when patients stop taking the treatment. Researchers deliberately took desensitized children off peanut SLIT for periods ranging from 1 to 17 weeks to measure how long the immune system changes would persist. The modeling data showed that on average, it would take approximately 22 weeks before desensitization would wear off and patients would become reactive to small amounts of peanut again. This durability matters in real life. "We know that life happens, and there may be times where the treatment is missed," Dr. Kim explained. "It could be because of vacation, or being sick, or just forgetting. This exciting new data shows that the changes to the immune system after peanut SLIT may not be permanent, but they are long-lasting". What Were the Actual Results From the Study? The trial included 54 peanut-allergic children, with 47 completing the full treatment course. The results demonstrated meaningful protection levels across the group: - Protection Against Accidental Exposure: 70% of children showed protection against accidental peanut exposures of more than 800 milligrams (approximately 3 peanuts) - Full Desensitization: 36% achieved full desensitization, tolerating 5,000 milligrams of peanut (roughly 16 peanuts) - Average Threshold Increase: The average threshold after treatment was 2,723 milligrams of peanut, compared to 1,700 milligrams using the lower 2-milligram dose in earlier pilot studies - Safety Profile: Only 4% of doses caused side effects, mostly temporary itching in the mouth, with no cases requiring epinephrine (EpiPen) treatment How Does SLIT Compare to Previous Peanut Allergy Treatments? This research builds on earlier work. In 2011, Dr. Kim's team conducted a pilot study showing that desensitization was possible with peanut SLIT in a placebo-controlled trial. When those children continued treatment for 5 years, the desensitization was maintained, the treatment remained safe, and a small group could even stop treatment for a month and still remain desensitized. The current trial was designed to answer two critical questions: Could higher doses be more effective, and how long-lasting could the treatment effect be? Researchers increased the dose from 2 milligrams to 4 milligrams and implemented the first-of-its-kind approach of deliberately stopping treatment to measure durability. Steps to Understanding If SLIT Might Work for Your Child - Discuss with Your Allergist: Talk to your child's allergist about whether sublingual immunotherapy is appropriate, as it's designed for children with confirmed peanut allergies who have experienced allergic reactions - Understand the Commitment: SLIT requires consistent daily dosing during the treatment phase, though the good news is that missed doses don't immediately erase protection due to the 22-week durability window - Know the Safety Profile: Review that the treatment has a strong safety record with only 4% of doses causing side effects, and no cases in this study required emergency epinephrine treatment - Explore Clinical Trial Options: Multiple peanut allergy immunotherapy trials are currently enrolling at UCLA and other research centers, including studies of the Viaskin Peanut patch for toddlers ages 1-3 and combination therapies for older children and adults Dr. Kim emphasized the real-world importance of this work: "As a father of two children who have had anaphylaxis to nuts, I know what life can be like for parents and children dealing with food allergies. We need a treatment that protects our children from the unexpected, but it needs to be safe and it needs to be simple". The research suggests that SLIT could represent a meaningful option for families seeking peanut allergy management that balances protection with simplicity. While not a cure, the treatment's ability to provide lasting desensitization with a straightforward daily dose and a strong safety record addresses a significant gap in current peanut allergy care.
